ClinicalTrials.gg
CompletedNCT01523392Updated Oct 8, 2014Results posted

A Pharmacodynamic Study With Ticagrelor in African American Patients

A Phase 4 interventional study of Ticagrelor and Clopidogrel in Stable Coronary Artery Disease, sponsored by AstraZeneca. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-08.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 78 studies testing ticagrelor in Coronary Artery Disease — 5 open to participants now, 5 under way, 2 of them phase 3. Ticagrelor · Coronary Artery Disease.

Enrollment
50th of 78
50 · median 80
Started
2012
with 6 others
Phase 4
46 of 78
3 open now
Registered
9th of 78
by date
Lead sponsor
9 of 78
AstraZeneca

Among the 78 studies testing ticagrelor in Coronary Artery Disease, this one is the 50th largest by enrollment, is one of 7 that started in 2012, is one of 46 in phase 4, and was the 9th registered.

Coronary Artery Disease

4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

5 of the 78 studies testing ticagrelor in Coronary Artery Disease are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ticagrelor

Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies testing ticagrelor in Coronary Artery Disease, or all of them as a file.
02

Study summary

The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in African American patients with stable coronary artery disease.

Read the detailed description

A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor versus Clopidogrel in African American Patients with Stable Coronary Artery Disease

03

Conditions studied

  • Stable Coronary Artery Disease

Keywords

  • Stable Coronary Artery Disease, CAD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated before initiation of any study-related procedures
  • Male or female patients aged 18 years or older
  • Documented stable CAD fulfilling and taking 75-100mg ASA daily treatment
  • Females must be post menopausal or surgically sterile Self-identified as African American

Exclusion criteria

Exclusion Criteria:

  • Any indication for oral anticoagulant (e.g., atrial fibrillation, mitral stenosis or prosthetic heart valve) or dual antiplatelet treatment (e.g., clopidogrel, prasugrel, ASA dose other than 75 to 100 mg daily) during study period
  • Patients who had ACS or stent placed within 12 months of screening Patients with a history of moderate or severe hepatic impairment
  • Current smokers, including the use of tobacco containing products in the past 1 month of randomization Patients required dialysis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Ticagrelor

    Drug: Ticagrelor

  • Active comparator
    Clopidogrel

    Drug: Clopidogrel

Interventions

  • Min - 90mg/Max - 180mg tablets (loading dose)

  • 75mg (once daily)/Max - 600mg tablets (loading dose)

06

What researchers measure

Primary outcomes

  1. Inhibition of the P2Y12 Receptor as Measured by Platelet Reaction Unit (PRU) From VerifyNow™ (a Platelet Function Test Developed by Accumetrics) at 2 Hours After Loading Dose

    Time frame: At 2 hours after the loading dose

Secondary outcomes

  1. Inhibition of the P2Y12 Receptor as Measured by PRU From VerifyNow™ at 0.5 Hour and 8 Hours After Loading Dose

    Time frame: At 0.5 hour and 8 hours after the loading dose

  2. Inhibition of the P2Y12 Receptor as Measured by PRU From VerifyNow™ at 2 Hours and 8 Hours on Day 7 After Multiple Doses and at End of Dosing Interval on Day 8

    Time frame: At 2 hours and 8 hours on Day 7 after multiple doses and at end of dosing interval on Day 8

  3. Ticagrelor Plasma Concentrations After the Loading and Maintenance Doses

    The standard deviation (SD) is the geometric SD

    Time frame: Predose, 0.5 hour, 2 hours, 8 hours from loading dose; 0, 2 hours, 8 hours and 12 hours from last dose

  4. AR-C124910XX (an Active Metabolite of Ticagrelor) Plasma Concentrations After the Loading and Maintenance Doses

    The standard deviation (SD) is the geometric SD

    Time frame: Predose, 0.5 hour, 2 hours, 8 hours from loading dose and 0, 2 hours, 8 hours and 12 hours from last dose

07

Results

Posted Sep 26, 2014

Participant flow

Patients recruited from 8 participating centers in the United States from 28 March 2012 until 04 September 2013

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneTicagrelor (Period 1) Then Clopidogrel (Period 2) SequenceClopidogrel (Period 1) Then Ticagrelor (Period 2) Sequence
Started2014
Completed1714
Not completed30
Withdrew: Withdrawal by subject20
Withdrew: Did not complete 7-9 days of treatment.10
Washout Period - 10 to 14 Days
Participant flow — Washout Period - 10 to 14 Days
MilestoneTicagrelor (Period 1) Then Clopidogrel (Period 2) SequenceClopidogrel (Period 1) Then Ticagrelor (Period 2) Sequence
Started1814
Completed1714
Not completed10
Withdrew: Adverse event10
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneTicagrelor (Period 1) Then Clopidogrel (Period 2) SequenceClopidogrel (Period 1) Then Ticagrelor (Period 2) Sequence
Started1714
Completed1714
Not completed00

Outcome measures

PrimaryInhibition of the P2Y12 Receptor as Measured by Platelet Reaction Unit (PRU) From VerifyNow™ (a Platelet Function Test Developed by Accumetrics) at 2 Hours After Loading Dose
Time frame:
At 2 hours after the loading dose
Reported as:
Least squares mean · PRU
Inhibition of the P2Y12 Receptor as Measured by Platelet Reaction Unit (PRU) From VerifyNow™ (a Platelet Function Test Developed by Accumetrics) at 2 Hours After Loading Dose
PRUTicagrelorClopidogrel
Inhibition of the P2Y12 Receptor as Measured by Platelet Reaction Unit (PRU) From VerifyNow™ (a Platelet Function Test Developed by Accumetrics) at 2 Hours After Loading Dose27.6 (4.9 to 50.2)211.2 (188.3 to 234.0)
Statistical analysis
  • Ticagrelor vs Clopidogrel · Mixed Models Analysis · p = <0.001 (Model contained treatment group, period, and sequence as fixed effects and a random effect for patient within sequence) · Mean difference (final values): -183.6 · 95% CI -213.9 to -153.3Ticagrelor minus clopidogrel
SecondaryInhibition of the P2Y12 Receptor as Measured by PRU From VerifyNow™ at 0.5 Hour and 8 Hours After Loading Dose
Time frame:
At 0.5 hour and 8 hours after the loading dose
Reported as:
Least squares mean · PRU
Inhibition of the P2Y12 Receptor as Measured by PRU From VerifyNow™ at 0.5 Hour and 8 Hours After Loading Dose
PRUTicagrelorClopidogrel
0.5 hours166.3 (137.9 to 194.8)270.1 (241.3 to 298.8)
8 hours (N=28 ticagrelor, N=27 clopidogrel)27.2 (4.3 to 50.2)192.6 (169.3 to 215.8)
Statistical analysis
  • Ticagrelor vs Clopidogrel · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -103.8 · 95% CI -142.5 to -65.0Ticagrelor minus clopidogrel
  • Ticagrelor vs Clopidogrel · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -165.3 · 95% CI -197.4 to -133.3Ticagrelor minus clopidogrel
SecondaryInhibition of the P2Y12 Receptor as Measured by PRU From VerifyNow™ at 2 Hours and 8 Hours on Day 7 After Multiple Doses and at End of Dosing Interval on Day 8
Time frame:
At 2 hours and 8 hours on Day 7 after multiple doses and at end of dosing interval on Day 8
Reported as:
Least squares mean · PRU
Inhibition of the P2Y12 Receptor as Measured by PRU From VerifyNow™ at 2 Hours and 8 Hours on Day 7 After Multiple Doses and at End of Dosing Interval on Day 8
PRUTicagrelorClopidogrel
2 hours on Day 7 (N=27 for clopidogrel)22.9 (1.4 to 44.4)157.8 (135.9 to 179.8)
8 hours on Day 728.5 (7.7 to 49.2)146.5 (125.6 to 167.4)
End of dosing interval on Day 839.3 (17.8 to 60.7)172.7 (151.2 to 194.2)
Statistical analysis
  • Ticagrelor vs Clopidogrel · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -135.0 · 95% CI -160.4 to -109.5Ticagrelor minus clopidogrel
  • Ticagrelor vs Clopidogrel · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -118.1 · 95% CI -143.9 to -92.2Ticagrelor minus clopidogrel
  • Ticagrelor vs Clopidogrel · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -133.4 · 95% CI -159.7 to -107.1Ticagrelor minus clopidogrel
SecondaryTicagrelor Plasma Concentrations After the Loading and Maintenance Doses

The standard deviation (SD) is the geometric SD

Time frame:
Predose, 0.5 hour, 2 hours, 8 hours from loading dose; 0, 2 hours, 8 hours and 12 hours from last dose
Reported as:
Geometric mean · ng/mL
Ticagrelor Plasma Concentrations After the Loading and Maintenance Doses
ng/mLTicagrelor (Treatment Period 1)Ticagrelor (Treatment Period 2)
Baseline (0 pre-dose hours)1.0 ± 1.01.2 ± 1.8
0.5 hours after the loading dose206.6 ± 5.233.7 ± 8.2
2 hours after the loading dose1167.3 ± 1.8756.9 ± 1.9
8 hours after the loading dose - Period 1 N=19395.9 ± 1.5141.9 ± 12.1
0 hours after multiple doses - Period 1 N=18168.4 ± 7.3187.4 ± 2.1
2 hours after multiple doses - Period 1 N=18324.6 ± 8.9608.8 ± 1.9
8 hours after multiple doses - Period 1 N=18179.2 ± 7.4311.3 ± 1.7
End of dosing interval on Day 8 - Period 1 N=18284.9 ± 2.2295.7 ± 1.9
SecondaryAR-C124910XX (an Active Metabolite of Ticagrelor) Plasma Concentrations After the Loading and Maintenance Doses

The standard deviation (SD) is the geometric SD

Time frame:
Predose, 0.5 hour, 2 hours, 8 hours from loading dose and 0, 2 hours, 8 hours and 12 hours from last dose
Reported as:
Geometric mean · ng/mL
AR-C124910XX (an Active Metabolite of Ticagrelor) Plasma Concentrations After the Loading and Maintenance Doses
ng/mLTicagrelor (Treatment Period 1)Ticagrelor (Treatment Period 2)
Baseline (0 pre-dose hours)1.0 ± 1.01.0 ± 1.0
0.5 hours after the loading dose9.8 ± 4.92.3 ± 3.2
2 hours after the loading dose222.6 ± 2.7150.9 ± 2.5
8 hours after the loading dose - Period 1 N=19119.0 ± 1.754.8 ± 7.5
0 hours after multiple doses - Period 1 N=1893.2 ± 5.874.5 ± 2.0
2 hours after multiple doses - Period 1 N=18136.7 ± 6.3172.3 ± 1.7
8 hours after multiple doses - Period 1 N=1889.8 ± 5.6112.6 ± 1.3
End of dosing interval on Day 8 - Period 1 N=18140.8 ± 1.9110.3 ± 1.4

Adverse events

Collected over Adverse events were collected from the time of signature of the informed consent throughout the treatment period including the follow up visit (approximately 11 weeks for each participant).. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ticagrelor—1/34 (2.9%)5/34 (14.7%)
Clopidogrel—0/31 (0%)2/31 (6.5%)
Most frequent serious events
Most frequent serious events
EventTicagrelorClopidogrel
Acute Myocardial InfarctionCardiac disorders1/340/31
Most frequent other events
Most frequent other events
EventTicagrelorClopidogrel
DyspnoeaRespiratory, thoracic and mediastinal disorders2/340/31
Application site bruiseGeneral disorders0/341/31
Vessel puncture site bruiseGeneral disorders0/341/31
Musculoskeletal painMusculoskeletal and connective tissue disorders0/341/31
Vaginal haemmorhageReproductive system and breast disorders0/341/31
Haemorroidal haemorrhageGastrointestinal disorders1/340/31
EpistaxisRespiratory, thoracic and mediastinal disorders1/340/31
Blood glucose decreasedInvestigations1/340/31
ContusionInjury, poisoning and procedural complications1/340/31

Baseline characteristics

Randomized Analysis Set for demography (N=34) - included all patients who signed informed consent and were randomized into the study.

Age, Customized
Age, Customized(Participants)Ticagrelor (Period 1) Then Clopidogrel (Period 2) SequenceClopidogrel (Period 1) Then Ticagrelor (Period 2) SequenceTotal
<18 years000
>=18 to <65 years121022
>= 65 years8412
Sex: Female, Male
Sex: Female, Male(Participants)Ticagrelor (Period 1) Then Clopidogrel (Period 2) SequenceClopidogrel (Period 1) Then Ticagrelor (Period 2) SequenceTotal
Female8311
Male121123
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ticagrelor (Period 1) Then Clopidogrel (Period 2) SequenceClopidogrel (Period 1) Then Ticagrelor (Period 2) SequenceTotal
Black or African American201434
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ticagrelor (Period 1) Then Clopidogrel (Period 2) SequenceClopidogrel (Period 1) Then Ticagrelor (Period 2) SequenceTotal
Not Hispanic or Latino201434
Region of Enrollment
Region of Enrollment(Participants)Ticagrelor (Period 1) Then Clopidogrel (Period 2) SequenceClopidogrel (Period 1) Then Ticagrelor (Period 2) SequenceTotal
United States201434
08

Study locations

8 sites
  • Research Site
    Newark, Delaware, United States
  • Research Site
    Wilmington, Delaware, United States
  • Research Site
    Washington, District of Columbia, United States
  • Research Site
    Hollywood, Florida, United States
  • Research Site
    Jacksonville, Florida, United States
  • Research Site
    Atlanta, Georgia, United States
  • Research Site
    Towson, Maryland, United States
  • Research Site
    Beaumont, Texas, United States
09

References and documents

Publications

  • Waksman R, Maya J, Angiolillo DJ, Carlson GF, Teng R, Caplan RJ, Ferdinand KC. Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease: Prospective, Randomized, Open-Label, Multiple-Dose, Crossover Pilot Study. Circ Cardiovasc Interv. 2015 Jul;8(7):e002232. doi: 10.1161/CIRCINTERVENTIONS.114.002232. PubMed 26152562 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2014, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2012
First posted
Feb 1, 2012
Start
Mar 2012
Primary completionActual
Sep 2013
CompletionActual
Sep 2013
Results first posted
Sep 26, 2014
Last update
Oct 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01523392
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 1, 2012
Start date
Mar 2012
Primary completion
Sep 2013
Completion
Sep 2013
Results posted
Sep 26, 2014
Last update
Oct 8, 2014

Study contacts

Glenn Carlson, MD
study director · AstraZeneca Pharmaceuticals Room C3B-718PO Box 15437 Wilmington, DE 19850-5437 USA
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ticagrelor

Start the discussion